Bevacizumab with FOLFOX for Metastatic Colorectal Cancer
Author Information
Author(s): Emmanouilides Christos, Sfakiotaki Georgia, Androulakis Nikolaos, Kalbakis Kostas, Christophylakis Charalambos, Kalykaki Antonia, Vamvakas Lambros, Kotsakis Athanasios, Agelaki Sofia, Diamandidou Eleni, Touroutoglou Nikolaos, Chatzidakis Adam, Georgoulias Vassilis, Mavroudis Dimitris, Souglakos John
Hypothesis
To evaluate the efficacy and the toxicity of front line FOLFOX4 combined with bevacizumab in patients with metastatic colorectal cancer.
Conclusion
The combination of FOLFOX4/bevacizumab appears to be highly effective, well tolerated and merits further evaluation in patients with metastatic colorectal cancer.
Supporting Evidence
- Fifty-three patients were enrolled in the study.
- The overall response rate was 67.9%.
- The median time to tumor progression was 11 months.
- The probability of 1-, 2-, and 3-year survival was 79.8%, 63.8%, and 58.3%, respectively.
- Grade 3–4 neutropenia occurred in 15.1% of patients.
Takeaway
This study tested a new treatment for patients with advanced colon cancer and found it works well and is safe.
Methodology
Chemotherapy-naïve patients with metastatic colorectal cancer received a combination of bevacizumab, oxaliplatin, leucovorin, and 5-fluorouracil every two weeks.
Potential Biases
Potential selection bias due to the non-randomized nature of the study.
Limitations
The study is a phase II trial, which may limit the generalizability of the results.
Participant Demographics
Median age of participants was 65 years, with 56.6% being male.
Statistical Information
P-Value
0.0023
Confidence Interval
95% C.I.: 53.8%–92%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website